Ep. 191 Optimizing Radiation Therapy: Role of Perirectal Spacers with Dr. Eric Chenven and Dr. Nadim Nasr

561.474 - 586.011 Dr. Nadim Nasr

Well, I want to agree with Eric. I think that we've mostly moved away from standard fractionation for prostate cancer. If you look at radiobiologic studies, what they actually show is that most prostate cancers respond a lot better to higher doses per treatment. And so I think we're going to see a significant move towards hyperfractionation in almost, you know, most of these cancers.